XPOVIO®
(selinexor) tablets Xpovio is a “nuclear export inhibitor,” the first medication in this drug class to treat myeloma. Nuclear export inhibitors prevent cancer cells from expelling “tumor suppressor proteins” that help protect the cell from cancer.
Who is a candidate for Xpovio? Xpovio is used in myeloma in both early relapse and late relapse settings. In 2019, supported by the results of the phase IIb STORM clinical trial, the U.S. Food and Drug Administration (FDA) approved Xpovio in combination with the steroid dexamethasone (Xd) for the treatment of adult patients with relapsed or refractory disease. In 2020, supported by the results of the BOSTON phase III clinical trial, the FDA approved Xpovio in combination with Velcade® (bortezomib) + dexamethasone (XVd) for myeloma patients who have received at least one prior therapy.
How is Xpovio taken? ¡ Each Xpovio tablet should be swallowed whole with water. Do not break, chew, crush, or divide the tablets. ¡ Your doctor will monitor your complete blood count (CBC), standard blood chemistry panel, and body weight before you start Xpovio and as needed during treatment. (continues on reverse side)